Chart Of The Day: Pfizer Pops But Still Isn't Immune To Bearish Retaliation

 | Jul 23, 2020 14:58

The US government has agreed to pay $2 billion dollars for up to 600 million doses of a vaccine against COVID-19 that Pfizer (NYSE:PFE) is developing, together with German biotechnology firm BioNtech (NASDAQ:BNTX), if it proves to be safe and effective.

The contract for 100 million doses of the vaccine is enough to inoculate 50 million people, based on a two-dose course of treatment, Reuters reported. If it's effective the government has an option to procure the remaining dosages.

Shares of Pfizer, the biggest US drugmaker, closed up 5.1% yesterday, marking the third rising gap this month for the stock, and the biggest one-day gain in percentage terms since Mar. 30. But this move is different. The price used the 200-DMA as a springboard to break above a downtrend line that had been in place for over a year.